Ability Pharma

Executive Summary

Ability Pharma is a clinical-stage biopharmaceutical company specializing in first-in-class, oral anticancer therapies that induce cytotoxic autophagy, a novel mechanism of action. Headquartered in Barcelona, Spain, the company leverages this unique approach to selectively kill cancer cells while sparing healthy tissues. Founded in 2009, Ability Pharma is advancing its lead candidate, ABTL0812, through clinical development for multiple solid tumor indications. The company's focus on autophagy induction differentiates it from traditional therapies and offers potential for improved efficacy and tolerability in oncology. ABTL0812 has completed Phase 1 trials and is now in Phase 2 studies for various solid tumors, including pancreatic cancer, endometrial cancer, and others. Early clinical data have shown encouraging safety profiles and signs of antitumor activity. The upcoming milestones include interim Phase 2 data readouts and potential expansion into later-stage trials. With a strong scientific foundation and a growing pipeline, ABTL0812 represents a promising therapeutic option. If successful, Ability Pharma could address significant unmet needs in cancer treatment. The company continues to seek partnerships and financing to support further development and eventual commercialization.

Upcoming Catalysts (preview)

• Q3 2026Interim Phase 2 data for ABTL0812 in pancreatic cancer60% success
• Q4 2026Initiation of Phase 2b/3 trial in endometrial cancer50% success
• H2 2026Potential licensing or partnership deal for ABTL081240% success